VivoSeq
Other

Empagliflozin

0

Pipeline Programs↗

14

Active Trials↗

8

Companies Involved↗

Empagliflozin is an early-stage landscape with 0 programs across 8 companies. The most active players are Boehringer Ingelheim, Gedeon Richter Plc., Chong Kun Dang Pharmaceutical.

Intelligence

Pipeline Metrics

Competitive Density

31/100

Pipeline Velocity

34/100

Mech. Concentration

N/A

Completion Rate

97/100

Attrition Rate

3/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Boehringer Ingelheim logo

Boehringer Ingelheim

0 programs

PreclinicalG

Gedeon Richter Plc.

0 programs

PreclinicalChong Kun Dang Pharmaceutical logo

Chong Kun Dang Pharmaceutical

0 programs

PreclinicalChia Tai Tianqing Pharmaceutical Group Co., Ltd. logo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

0 programs

PreclinicalI

Intarcia Therapeutics

0 programs

PreclinicalG

Getz Pharma

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

117

clinical trials

Completed86 · 74%
Unknown status14 · 12%
Recruiting8 · 7%
Not yet recruiting4 · 3%
Active, not recruiting2 · 2%
Withdrawn2 · 2%
Other1 · 1%

Clinical Trials

Trial Activity

117 trials

Effect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With NDKD
Recruiting·WWashington D.C. Veterans Affairs Medical Center·Phase 4·NCT06110130·60 enrolled
A Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Through Cluster Randomization Embedded in the Electronic Health Record
Recruiting·HHerlev and Gentofte Hospital·Phase 4·NCT06642272·17,200 enrolled
Use of Flozins (Empagliflozin/Dapagliflozin) for Prevention of AKI
Recruiting·CCollegium Medicum w Bydgoszczy·N/A·NCT07231939·4,000 enrolled
Real World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in T2DM Patients - EASE Study
Recruiting·GGetz Pharma·Phase 4·NCT05164263·2,000 enrolled
Effect of Empagliflozin on Inflammation
Recruiting·HHotel Dieu de France Hospital·Phase 4·NCT07292909·100 enrolled
A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin
Recruiting·HHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.·Phase 1·NCT07331389·111 enrolled
Effect of Empagliflozin on Metabolic Outcomes in Adults Living With HIV Receiving Dolutegravir-Based Therapy
Recruiting·—·Phase 2·NCT07336797·66 enrolled
Empagliflozin in ESKD - A Feasibility Study
Recruiting·UUniversity of Mississippi Medical Center·Phase 1/2·NCT05687058·24 enrolled
Use of Empagliflozin to Treat Prediabetes
Active, not recruiting·OOregon State University·Phase 4·NCT05426525·60 enrolled
Evaluation of the Use of Empagliflozin in Patients with HF with PEF in a Cardiology Outpatient Department
Active, not recruiting·CConrado Roberto Hoffmann Filho·Phase 3·NCT06683053·90 enrolled
SGLT2 Inhibition With Empagliflozin in Fontan Circulatory Failure
Not yet recruiting·—·Phase 3·NCT06955260·410 enrolled
Empagliflozin as a Potential Therapeutic Solution for Patients With Brugada Syndrome
Not yet recruiting·NNational Taiwan University Hospital·Phase 2·NCT07146880·10 enrolled
Effect of Empagliflozin in Patients With eGFR Between 10 and 20 ml/Min/1.73m2
Not yet recruiting·—·Phase 4·NCT07074418·34 enrolled
Bioequivalence Study of Empagliflozin 25 mg Film-coated Tablets in Healthy Thai Volunteers
Not yet recruiting·IInternational Bio service·Phase 1·NCT06337409·30 enrolled
EXpanded Combination of Evolocumab Plus Empagliflozin on Diabetes: EXCEED-BHS3 Trial
Completed·UUniversity of Campinas, Brazil·Phase 4·NCT03932721·110 enrolled
Page 1 of 8

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)